36.88
price up icon0.33%   0.12
 
loading
Gsk Plc Adr stock is traded at $36.88, with a volume of 6.85M. It is up +0.33% in the last 24 hours and down -8.49% over the past month. In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$36.76
Open:
$37.59
24h Volume:
6.85M
Relative Volume:
1.52
Market Cap:
$75.24B
Revenue:
$39.71B
Net Income/Loss:
$3.17B
P/E Ratio:
10.71
EPS:
3.4423
Net Cash Flow:
$6.05B
1W Performance:
-1.71%
1M Performance:
-8.49%
6M Performance:
-13.37%
1Y Performance:
+6.65%
1-Day Range:
Value
$36.85
$37.60
1-Week Range:
Value
$36.07
$38.26
52-Week Range:
Value
$33.67
$45.92

Gsk Plc Adr Stock (GSK) Company Profile

Name
Name
Gsk Plc Adr
Name
Phone
-
Name
Address
-
Name
Employee
70,200
Name
Twitter
@GSK
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
GSK's Discussions on Twitter

Gsk Plc Adr Stock (GSK) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-08-24 Downgrade UBS Buy → Neutral
May-30-24 Initiated Goldman Neutral
Mar-04-24 Upgrade Guggenheim Neutral → Buy
Feb-13-24 Upgrade Citigroup Neutral → Buy
Jan-23-24 Initiated Morgan Stanley Equal-Weight
Jan-16-24 Resumed UBS Buy
Jan-03-24 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Reduce
Mar-17-23 Upgrade Deutsche Bank Hold → Buy
Feb-27-23 Resumed Goldman Buy
Jan-03-23 Downgrade JP Morgan Neutral → Underweight
Dec-05-22 Downgrade BofA Securities Neutral → Underperform
Nov-11-22 Downgrade UBS Neutral → Sell
Sep-15-22 Upgrade Credit Suisse Underperform → Neutral
Sep-08-22 Downgrade Jefferies Buy → Hold
Aug-05-22 Resumed Morgan Stanley Equal-Weight
Jul-21-22 Resumed Citigroup Neutral
Feb-11-22 Downgrade DZ Bank Buy → Hold
Nov-05-21 Upgrade Barclays Underweight → Equal Weight
Jun-24-21 Upgrade Deutsche Bank Sell → Hold
Mar-23-21 Downgrade SVB Leerink Outperform → Mkt Perform
Feb-04-21 Downgrade Deutsche Bank Hold → Sell
Jan-20-21 Downgrade Credit Suisse Neutral → Underperform
Jan-15-21 Initiated Deutsche Bank Hold
Nov-02-20 Upgrade Liberum Hold → Buy
Sep-29-20 Initiated Berenberg Buy
Feb-12-20 Downgrade Shore Capital Hold → Sell
Jan-16-20 Downgrade Barclays Equal Weight → Underweight
Dec-02-19 Initiated SVB Leerink Outperform
Nov-21-19 Upgrade UBS Neutral → Buy
Oct-11-19 Upgrade Cantor Fitzgerald Hold → Buy
Sep-03-19 Resumed Citigroup Neutral
Sep-03-19 Upgrade Societe Generale Sell → Buy
Aug-13-19 Resumed JP Morgan Neutral
Jun-17-19 Resumed Morgan Stanley Underweight
Mar-08-19 Downgrade Shore Capital Buy → Hold
Feb-22-19 Downgrade UBS Buy → Neutral
Jan-14-19 Downgrade Exane BNP Paribas Outperform → Neutral
Dec-11-18 Resumed Jefferies Buy
Oct-09-18 Initiated Guggenheim Neutral
Aug-30-18 Downgrade Liberum Buy → Hold
Apr-04-18 Upgrade Exane BNP Paribas Neutral → Outperform
Mar-22-18 Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-09-18 Upgrade Kepler Reduce → Hold
View All

Gsk Plc Adr Stock (GSK) Latest News

pulisher
Nov 01, 2024

GSK Plc ADR (NYSE: GSK) Has Outstanding Potential - Stocks Register

Nov 01, 2024
pulisher
Oct 31, 2024

Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak - GlobeNewswire Inc.

Oct 31, 2024
pulisher
Oct 29, 2024

What Do Analysts Think About ICICI Bank Ltd. ADR’s (NYSE:IBN) Future? - Stocks Register

Oct 29, 2024
pulisher
Oct 28, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Oct 28, 2024
pulisher
Oct 25, 2024

GSK Plc ADR (GSK): An Important Analyst Insights - Stocks Register

Oct 25, 2024
pulisher
Oct 21, 2024

5 Stocks to Buy if You’re Concerned About US Market Valuations - Morningstar

Oct 21, 2024
pulisher
Oct 18, 2024

21 Best Healthcare Companies to Invest In - Morningstar

Oct 18, 2024
pulisher
Oct 16, 2024

Current share price is - GSK

Oct 16, 2024
pulisher
Oct 15, 2024

D-Wave Quantum Inc (QBTS) rating initates by B. Riley Securities - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

GSK's Studies On Depemokimab For Nasal Polyps Meet Primary Goals - Barchart

Oct 15, 2024
pulisher
Oct 15, 2024

Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.

Oct 15, 2024
pulisher
Oct 15, 2024

GSK Plc ADR [GSK] is 5.59% higher this YTD. Is it still time to buy? - The DBT News

Oct 15, 2024
pulisher
Oct 14, 2024

What You Didn’t Know About General Motors Company (NYSE: GM) This Week - Stocks Register

Oct 14, 2024
pulisher
Oct 14, 2024

GSK’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Oct 14, 2024
pulisher
Oct 14, 2024

Before You Invest, Make Sure You Check This ADT Inc (NYSE: ADT) Analysis - Stocks Register

Oct 14, 2024
pulisher
Oct 14, 2024

What Are You Thinking About Investing In Medical Properties Trust Inc (NYSE: MPW) Stock? - Stocks Register

Oct 14, 2024
pulisher
Oct 10, 2024

Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday - sharewise

Oct 10, 2024
pulisher
Oct 10, 2024

Introducing Our Rant Against GSK Plc ADR - US Post News

Oct 10, 2024
pulisher
Oct 09, 2024

Balance Sheet Insights: GSK Plc ADR (GSK)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Oct 09, 2024
pulisher
Oct 09, 2024

Pilgrim’s Pride Corp. (PPC) receives an Equal-weight rating from Stephens - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Berenberg upgrades Carnival plc ADR (CUK) stock to a Hold - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

JP Morgan analysts downgrades an Underweight rating for Organon & Co. (OGN) - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

GSK Plc ADR (GSK) gets rating Downgrade from UBS - Knox Daily

Oct 09, 2024
pulisher
Oct 08, 2024

GSK Plc ADR (GSK) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Oct 08, 2024
pulisher
Oct 07, 2024

Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine

Oct 07, 2024
pulisher
Oct 07, 2024

Precidian to List First ADRhedged Securities in the U.S. on Cboe, Providing Exposure to Individual International Companies with an Embedded Currency Hedge - PR Newswire

Oct 07, 2024
pulisher
Oct 04, 2024

Tenet Healthcare Corp. [THC] stock for 1,879,734 USD was sold by Ramsey R. Scott - Knox Daily

Oct 04, 2024
pulisher
Oct 03, 2024

Ratio Analysis: Unpacking GSK Plc ADR (GSK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 03, 2024
pulisher
Oct 02, 2024

GSK Plc ADR [GSK] Insider Activity: An Update for Investors - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

GSK Plc ADR (GSK) Stock: Navigating a Year of Stock Volatility - The InvestChronicle

Oct 02, 2024
pulisher
Oct 02, 2024

Cantor Fitzgerald’s latest rating for AMGN stock - Knox Daily

Oct 02, 2024
pulisher
Sep 27, 2024

Nutanix Inc [NTNX] Chief Financial Officer makes an insider sale of 24,316 shares worth 1,430,939. - Knox Daily

Sep 27, 2024
pulisher
Sep 26, 2024

GSK’s Stock Market Adventure: 9.44% YTD Growth Amidst Volatility - The InvestChronicle

Sep 26, 2024
pulisher
Sep 26, 2024

GSK Shares Experience Decline in Value - Knox Daily

Sep 26, 2024
pulisher
Sep 24, 2024

Ratio Revelations: GSK Plc ADR (GSK)’s Financial Metrics in the Spotlight - The Dwinnex

Sep 24, 2024
pulisher
Sep 23, 2024

Why GSK (GSK) is a Top Value Stock for the Long-Term - Yahoo Finance Australia

Sep 23, 2024
pulisher
Sep 20, 2024

Things To Consider Before You Buy GSK Plc ADR (NYSE: GSK) - Stocks Register

Sep 20, 2024
pulisher
Sep 19, 2024

GSK Plc ADR [GSK] Is Currently -0.31 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Sep 19, 2024
pulisher
Sep 19, 2024

GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines - Zacks Investment Research

Sep 19, 2024
pulisher
Sep 18, 2024

Behind GSK Plc ADR’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle

Sep 18, 2024

Gsk Plc Adr Stock (GSK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$89.51
price up icon 0.78%
drug_manufacturers_general SNY
$53.27
price up icon 0.74%
drug_manufacturers_general PFE
$28.09
price down icon 0.74%
$319.22
price down icon 0.29%
drug_manufacturers_general NVS
$109.35
price up icon 0.88%
drug_manufacturers_general MRK
$101.88
price down icon 0.43%
Cap:     |  Volume (24h):